Collaboration focuses on AI-discovered oncology asset in license deal worth $550m – highlights growing significance of AI in drug discovery.
Insilico Medicine, a company at the forefront of using AI for drug discovery, has announced a second exclusive global licensing agreement with Menarini Group’s Stemline Therapeutics division. The partnership centers on an oncology drug candidate developed using Insilico’s proprietary AI-driven platforms, and the deal, which has a total value of up to $550 million, signals a continued confidence in AI-generated assets for high-unmet-need areas within medicine.
The asset involved in the partnership has completed the preclinical stage and will now be advanced by Menarini Stemline, which will oversee clinical development, regulatory approvals, and commercialization. Insilico will receive an upfront payment, milestone payments contingent on clinical and regulatory success, and royalties on potential sales.
Longevity.Technology: The agreement illustrates Insilico’s strategic approach to partnerships, leveraging its AI discovery engines to identify and refine assets with significant therapeutic potential. This capability enables the company to be selective about its collaborators, ensuring alignment with organizations that share its vision for advancing effective therapies to patients. With its increasing success, Insilico has the flexibility to target research areas in aging,a field where AI is proving transformative in identifying new pathways and targets.
“We are thrilled to enter our second collaboration with Insilico Medicine, a leader in the field of generative AI, for a highly selective and potentially best-in-class small molecule targeting a broad range of cancers,” said Elcin Barker Ergun, CEO of the Menarini Group. “This asset will help us enter into new areas of high unmet need, expanding the tumor areas where we can help cancer patients with ground-breaking therapies [1].”
“Our previous experience with Menarini Stemline proved that the company is efficient, agile, strategic, and committed to rapidly delivering the best novel therapeutic solutions to patients with cancer, maximizing the probability of success of the program,” said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine.
“Menarini Stemline’s strategic visionary management is rapidly re-shaping the field of oncology, and we are very happy to take part in their quest to extend patients’ lives around the world [1].”
An evolving collaboration
This latest agreement builds upon the companies’ previous licensing agreement in January 2024, which focused on MEN2312, an innovative small molecule for breast cancer treatment and other oncology indication which was discovered and designed using Insilico’s AI technology.
Menarini paid $12 million upfront last year for licensing rights to the KAT6 inhibitor in a deal potentially worth more than $500 million; they will pay $20 million upfront for this latest asset, which Menarini Stemline, the oncology division of the Menarini Group, is well-positioned to take forward due to its established expertise in the oncology field. The company, which focuses on developing and commercialising novel, first-in-class or advanced oncology therapeutics, has a strong track record in bringing innovative cancer treatments to market.
AI as a driver of innovation
Insilico Medicine has rapidly established itself as a key player in the intersection of AI and drug development. Its discovery engines use deep learning models to identify novel therapeutic targets, design molecules and optimize preclinical candidates for a range of diseases, including oncology, fibrosis and aging-related conditions.
Zhavoronkov highlighted the broader implications of this collaboration in a statement on X, noting: “There are always many suitors for the hottest Insilico assets, but we believe that Menarini Stemline has the highest probability of success.” He praised Menarini’s expertise and commitment, emphasizing their ability to navigate the complexities of clinical development and regulatory approval.
Significance for oncology and beyond
The agreement aligns with a broader trend of integrating AI-driven technologies into drug discovery pipelines, which many experts believe can address bottlenecks in traditional pharmaceutical development; by accelerating the discovery process and enabling a more precise targeting of diseases, AI has the potential to significantly reduce the time and cost of bringing new treatments to market.
Insilico’s success also highlights the importance of carefully selecting partners who can deliver on the promise of its discoveries. As Zhavoronkov noted, large pharmaceutical companies with overcrowded pipelines may struggle to prioritize innovative assets – highlighting the advantage of collaborating with agile, specialized firms like Menarini Stemline.
Looking to the future
The partnership’s $550 million value demonstrates a growing confidence in AI’s potential to transform oncology and other therapeutic areas. For Insilico, the revenue from such deals provides an opportunity to deepen its focus on emerging fields, including aging-related diseases and interventions. This strategic reinvestment could help advance therapies aimed at improving healthspan and delaying the onset of age-related conditions.
As AI continues to shape the pharmaceutical landscape, collaborations like the one between Insilico Medicine and Menarini Stemline are likely to become increasingly common. And this is good news as partnerships like these can not only accelerate the development of innovative treatments but also set a benchmark for how AI can be effectively integrated into the global healthcare ecosystem.
